Mitochondrial Dysfunction and Disease Progression

Relapsing-Remitting Multiple Sclerosis Clinical Trial

Official title:

Mitochondrial Dysfunction and Disease Progression

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02549703
• Other study ID #: GCO 14-1495
• Secondary ID: CDMRP-MS140072
• Status: Completed
• Start date: September 2015
• Est. completion date: September 27, 2018

Study information

• Verified date: February 2019
• Source: Icahn School of Medicine at Mount Sinai
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

While the last several years have seen great strides in the treatment of relapsing forms of MS, progressive MS, responsible for the majority of MS-related disability, lags far behind. Despite much research, the lack of understanding related to what causes patients' relentless decline in function results in an inability to develop targeted treatment strategies suitable for clinical trials. This grant has two main goals.

The first goal is to extend the investigators preliminary study on rat neurons treated with the CSF of MS patients to a larger number of Progressive patients in order to validate the initial findings and extend the study to include analysis of human neurons. The initiating PI (Dr. Casaccia) and the Partnering PI and Clinical Neurologist (Dr. Katz Sand) have recently identified components that are present in the CSF of progressive patients that impair the ability of rat neurons to produce energy. The partnering PI, Dr. Quinzii (Columbia University) together with collaborator Dr. Fossati (NY Stem Cells Foundation), have characterized human neurons generated from stem cells derived from skin biopsies of progressive patients and detected the presence of energetic deficits. The experimental plan will build on these results and test hypotheses of disease progression. The overall goal is to improve understanding on how to stop neurons from degenerating and stop clinical progression.

The second goal is to ask whether it is possible to define a progressive disease course on the basis of combined biochemical, functional and imaging measurements. The initiating PI will be responsible for the biochemical assessment of CSF and serum samples and, together with partnering PI Quinzii, will also provide functional bioassays measurements of mitochondrial bioenergetics impairment in patients. These data will be combined with clinical assessment and MRI evaluations conducted by the partnering PI Katz Sand and collaborator Inglese. A two year clinical and imaging follow up from the initial recruitment will allow to define whether the combined measurements can be used by clinical neurologists to define the disease course and better identify therapeutic options for patients.

The expectation is that the completion of the stated aims of research will allow an advancement of the current knowledge of the progressive form of MS and lead to potential new therapeutic targets.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 47
• Est. completion date: September 27, 2018
• Est. primary completion date: September 27, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• male and female subjects age 18 or older

• diagnosis of one of the following:

1. RRMS according to McDonald 2010 criteria or a diagnosis of CIS with clinical symptoms and MRI consistent with MS

2. PPMS according to McDonald 2010 criteria

3. SPMS defined as at least six months of progressive decline following an initial relapsing disease course

• able and willing to undergo clinical evaluation, MRI, lumbar puncture, and skin biopsy and to return for follow up assessments at the end of year 1 and year 2

• able and willing to provide informed consent.

Exclusion criteria:

• pregnancy

• inability to undergo lumbar puncture, due to anticoagulant therapy that cannot be held for the day of the procedure or results of screening laboratory testing or the presence of another medical condition that would render the procedure unsafe, as determined by the investigator

• inability to undergo MRI, due to the presence of metallic implants incompatible with MRI or any other reason

• presence of other severe medical conditions likely to influence study results or that raise the likelihood of harm to the patient as a result of study participation, as determined by the investigator (e.g. the presence of a brain mass, which could influence the CSF results and also might make lumbar puncture unsafe)

• inability to complete the protocol for any reason

Related Conditions & MeSH terms

• Clinically Isolated Syndrome
• Disease Progression
• Multiple Sclerosis
• Multiple Sclerosis, Chronic Progressive
• Multiple Sclerosis, Relapsing-Remitting
• Primary Progressive Multiple Sclerosis
• Relapsing-Remitting Multiple Sclerosis
• Sclerosis
• Secondary Progressive Multiple Sclerosis

Locations

Country	Name	City	State
United States	Icahn School of Medicine	New York	New York

Sponsors (3)

Lead Sponsor	Collaborator
Icahn School of Medicine at Mount Sinai	Columbia University, The New York Stem Cell Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Spare respiratory capacity	Mitochondrial bioenergetic measurements	2 years
Primary	Oxygen consumption rate	Mitochondrial bioenergetic measurements	2 years
Secondary	Multiple Sclerosis Functional Composite (MSFC) Score	MS disease progression as measured by MSFC score which consists of the Timed 25-foot walk (T25FW) as a measure of ambulation, the Nine-hole peg test (9HPT) as a measure of arm and hand function.	1 year
Secondary	Multiple Sclerosis Functional Composite (MSFC) Score	MS disease progression as measured by MSFC score which consists of the Timed 25-foot walk (T25FW) as a measure of ambulation, the Nine-hole peg test (9HPT) as a measure of arm and hand function.	2 years
Secondary	Expanded Disability Status Scale	a formalized version of the neurological examination	2 years
Secondary	MS Impact Scale-29 (MSIS-29)	a quality of life measure; an overall measure of functioning from the patient's perspective	2 years